Apparent transient effects of recent "ecstasy" use on cognitive performance and extrapyramidal signs in human subjects

Cognitive and Behavioral Neurology

Volumn 19, Issue 3, 2006, Pages 157-164

  Smith, Ryan M ^a   Tivarus, Madalina ^a   Campbell, Heather L ^a   Hillier, Ashleigh ^a   Beversdorf, David Q ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Cognition; Ecstasy; Executive function; Frontal lobe; MDMA; Memory

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE;

ADULT; ARTICLE; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; EXTRAPYRAMIDAL SYNDROME; FEMALE; HUMAN; INTELLIGENCE QUOTIENT; LEARNING; MALE; MEMORY; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; RECALL; SLEEP DEPRIVATION; SOCIOECONOMICS; TASK PERFORMANCE;

ADULT; ANALYSIS OF VARIANCE; BASAL GANGLIA DISEASES; BLINKING; COGNITION; COGNITION DISORDERS; EXTRAPYRAMIDAL TRACTS; FEMALE; FRONTAL LOBE; HALLUCINOGENS; HUMANS; MALE; MATCHED-PAIR ANALYSIS; MOTOR SKILLS; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NEUROPSYCHOLOGICAL TESTS; PARKINSONIAN DISORDERS; PILOT PROJECTS; PROBLEM SOLVING; REFERENCE VALUES; TIME FACTORS; VERBAL LEARNING;

EID: 33748518911     PISSN: 15433633     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.wnn.0000213909.41901.cc     Document Type: Article

References (74)

1. Johnston LD, O'Malley PM, Bachman JG, et al. Monitoring the Future National Survey Results on Adolescent Drug Use: Overview of Key Findings, 2003. (NIH Publication No. 04-5506). Bethesda MD: National Institute on Drug Abuse; 2004.
2. Harris DS, Baggott M, Mendelson JH, et al. Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology. 2002;162:396-405.
3. Green AR, Mechan AO, Elliot JM, et al. The Pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy"). Pharmacol Rev. 2003;55:463-508.
4. Curran HV, Travill RA. Mood and cognitive effects of ±3,4- methylenedioxymethamphetamine (MDMA, 'ecstasy'): week-end 'high' followed by mid-week low. Addiction. 1997;92:821-831.
5. Parrott AC, Lasky J. Ecstasy (MDMA) effects upon mood and cognition: before, during and after a Saturday night dance. Psychopharmacology. 1998;139:261-268.
6. Kuypers KP, Ramaekers JG. Transient memory impairment after acute dose of 75 mg 3.4-methylene-dioxymethamphetamine. J Psychopharmacol. 2005;19:633-639.
7. Morgan MJ. Recreational use of "ecstasy" (MDMA) is associated with elevated impulsivity. Neuropsychopharmacology. 1998;19:252-264.
8. Bhattachary S, Powell JH. Recreational use of 3,4- methylenedioxymethamphetamine (MDMA) or 'ecstasy': evidence for cognitive impairment. Psychol Med. 2001;31:647-658.
9. McCardle K, Luebbers S, Carter JD, et al. Chronic MDMA (ecstasy) use, cognition and mood. Psychopharmacology. 2004;173:434-439.
10. Bolla KI, McCann UD, Ricaurte GA. Memory impairment in abstinent MDMA ("ecstasy") users. Neurology. 1998;51:1532-1537.
11. Morgan MJ. Memory deficits associated with recreational use of "ecstasy" (MDMA). Psychopharmacology. 1999;141:30-36.
12. Fox HC, McLean A, Turner JJD, et al. Neuropsychological evidence of a relatively selective profile of temporal dysfunction in drug-free MDMA ("ecstasy") polydrug users. Psychopharmacology. 2002;162:203-214.
13. Gouzoulis-Mayfrank E, Thimm B, Rezk M, et al. Memory impairment suggests hippocampal dysfunction in abstinent ecstasy users. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27:819-827.
14. Zakzanis KK, Young DA. Memory impairment in abstinent MDMA ("ecstasy") users: a longitudinal investigation. Neurology. 2001;56:966-969.
15. Gouzoulis-Mayfrank E, Fischermann T, Rezk M, et al. Memory performance in polyvalent MDMA (ecstasy) users who continue or discontinue MDMA use. Drug Alcohol Depend. 2005;78:317-323.
16. Dafters RI, Duffy F, O'Donnell PJ, et al. Level of use of 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) in humans correlates with EEG power and coherence. Psychopharmacology. 1999;145:82-90.
17. Zakzanis KK, Young DA. Executive function in abstinent MDMA ('ecstasy') users. Med Sci Monit. 2001;7:1292-1298.
18. Fox HC, Parrott AC, Turner JJD. Ecstasy use: cognitive deficits related to dosage rather than self-reported problematic use of the drug. J Psychopharmacol. 2001;15:273-281.
19. Halpern JH, Pope HG Jr, Sherwood AR, et al. Residual neuropsychological effects of illicit 3,4-methylenedioxymethamphetamine (MDMA) in individuals with minimal exposure to other drugs. Drug Alcohol Depend. 2004;75:135-147.
20. McCann UD, Szabo Z, Scheffel U, et al. Positron emission tomographic evidence of toxic effect of MDMA ("ecstasy") on brain serotonin neurons in human beings. Lancet. 1998;352:1433-1437.
21. Buchert R, Thomasius R, Wilke F, et al. A voxel-based PET investigation of the long-term effects of "ecstasy" consumption on brain serotonin transporters. Am J Psychiatry. 2004;161:1181-1189.
22. Daumann J, Fischermann T, Heekeren K, et al. Memory-related hippocampal dysfunction in poly-drug ecstasy (3,4-methylenedioxymethamphetamine) users. Psychopharmacology. 2005;180:607-611.
23. 11C]DASB. Neuropsychopharmacology. 2005;30:1741-1750.
24. Reneman L, Booij J, de Bruin K, et al. Effects of dose, sex, and long-term abstention from use on toxic effects of MDMA (ecstasy) on brain serotonin neurons. Lancet. 2001;358:1864-1869.
25. Kish SJ. How strong is the evidence that brain serotonin neurons are damaged in human users of ecstasy? Pharmacol Biochem Behav. 2002;71:845-855.
26. Reneman L, Majoie C, Schmand B, et al. Prefrontal N-acetylaspartate is strongly associated with memory performance in (abstinent) ecstasy users: preliminary report. Biol Psychiatry. 2001;50:550-554.
27. Reneman L, Majoie C, Flick H, et al. Reduced N-acetylaspartate levels in the frontal cortex of 3,4-methylenedioxymethamphetamine (ecstasy) users: preliminary results. AJNR Am J Neuroradiol. 2002;23:231-237.
28. Arrue A, Ruiz-Ortega JA, Ugedo L, et al. Short-term effects of 3,4-methylenedioxymethamphetamine on noradrenergic activity in the locus coeruleus and hippocampus of the rat. Neurosci Lett. 2003;337:123-126.
29. Piercy MF, Lum JT, Palmer JR. Effects of MDMA ('ecstasy') on firing rates of serotonergic, dopaminergic, and noradrenergic neurons in the rat. Brain Res. 1990;526:203-206.
30. Usher M, Cohen J, Servan-Shreiber D, et al. The role of locus coeruleus in the regulation of cognitive performance. Science. 1999;283:549-554.
31. Schmidt CJ. Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. J Pharmacol Exp Ther. 1987;240:1-7.
32. Stone DM, Merchan KM, Hanson GR, et al. Immediate and long term effects of 3,4-methylenedioxymethamphetamine on serotonin pathways in brain of rat. Neuropharmacology. 1987;26:1677-1683.
33. Schmidt CJ, Taylor VL. Depression of rat brain tryptophan hydroxylase following the acute administration of methylenedioxymethamphetamine. Biochem Pharmacol. 1987;36:4095-4102.
34. Hölscher C, Anwyl R, Rowan MJ. Stimulation on the positive phase of hippocampal theta rhythm induces long-term potentiation that can be depotentiated by stimulation on the negative phase in area CA1 in vivo. J Neurosci. 1997;17:6470-6477.
35. Vertes RP, Kocsis B. Brainstem-diencephalo-septohippocampal systems controlling the theta rhythm of the hippocampus. Neuroscience. 1997;81:893-926.
36. Gulyás AI, Acsády L, Freund TF. Structural basis of the cholinergic and serotonergic modulation of GABAergic neurons in the hippocampus. Neurochem Int. 1999;34:359-327.
37. Mintzer S, Hickenbottom S, Gilman S. Parkinsonism after taking ecstasy. N Engl J Med. 1999;340:1443.
38. Kuniyoshi SM, Jankovic J. MDMA and parkinsonism. N Engl J Med. 2003;349:96-97.
39. O'Suilleabhain P, Giller C. Rapidly progressive parkinsonism in a self-reported user of ecstasy and other drugs. Mov Disord. 2003;18:1378-1381.
40. Ricaurte GA, Yuan J, Hatzidimitriou G, et al. Severe dopaminergic neurotoxicity in primates after a common recreational dose regimen of MDMA ("ecstasy"). Science. 2002;297:2260-2263.
41. Ricaurte GA, Yuan J, Hatzidimitriou G, et al. Retraction. Science. 2003;301:1479.
42. Colado MI, O'Shea E, Green AR. Acute and long-term effects of MDMA on cerebral dopamine biochemistry and function. Psychopharmacology. 2004;173:249-263.
43. Kita T, Wagner GC, Nakashima T. Current research on methamphetamine- induced neurotoxicity: animal models of monoamine disruption. J Pharmacol Sci. 2003;92:178-185.
44. Karson CN, LeWitt PA, Calne DB, et al. Blink rates in parkinsonism. Ann Neurol. 1982;12:580-583.
45. Karson CN, Burns RS, LeWitt PA, et al. Blink rates and disorders of movement. Neurology. 1984;34:677-678.
46. Sandyk R. The significance of eye blink rate in parkinsonism: a hypothesis. Int J Neurosci. 1990;51:99-103.
47. Deuschl G, Goddemeier C. Spontaneous and reflex activity of facial muscles in dystonia, Parkinson's disease, and in normal subjects. J Neurol Neurosurg Psychiatry. 1998;64:320-324.
48. Farré M, de la Torre R, Ó Mathúna B, et al. Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics. Psychopharmacology. 2004;173:364-375.
49. Nelson HE, Willison J. National Adult Reading Test (NART): Test Manual. 2nd ed. Windsor, UK: NFER Nelson; 1991.
50. Blair JR, Spreen O. Predicting premorbid IQ, a revision of the National Adult Reading Test. Clin Neuropsychol. 1989;3:129-136.
51. Berg EA. A simple objective technique for measuring flexibility in thinking. J Gen Psychol. 1948;39:15-22.
52. Grant DA, Berg EA. A behavioral analysis of degree of impairment and ease of shifting to new responses in a Weigle-type card sorting problem. J Exp Psychol. 1948;39:404-411.
53. Raven JC. Sets C-E (Standard Progressive Matrices.). Oxford, England: Oxford Psychologists Press; 1976.
54. Raven J, Raven JC, Court JH. Standard Progressive Matrices: Raven Manual Section 3. Oxford, UK: Oxford Psychologists Press; 2000.
55. Beversdorf DQ, White DM, Chever DC, et al. Central beta-adrenergic modulation of cognitive flexibility. Neuroreport. 2002;13:2505-2507.
56. Stroop JR. Studies of interference in serial verbal reaction. J Exp Psychol. 1935;18:643-662.
57. Spreen O, Strauss E. In: A Compendium of Neuropsychological Tests. 2nd ed. Controlled Oral Word Association (COWA). New York: Oxford University Press; 1998:447-464.
58. Delis DC, Kramer JH, Kaplan E, et al. California Verbal Learning Test - Second Edition: Adult Version. San Antonio: The Psychological Corporation, Harcourt Assessment Company; 2000.
59. Rey A. L'examen psychologique dans les cas d'encephalopathie traumatique. Arch Psychol. 1941;28:286-340.
60. Osterrieth PA. Le test de copie d'une figure complex: Contribution a l'étude de la perception et de la mémoire. Arch Psychol. 1944;30:286-356.
61. Taylor EM. Psychological Appraisal of Children With Cerebral Deficits. Cambridge, MA: Harvard University Press; 1959.
62. Fahn S, Elton RL. UPDRS program members. In: Fahn S, Marsden CD, Goldstein M, et al. eds, Recent Developments in Parkinsons Disease, Unified Parkinsons Disease Rating Scale. vol 2. Florham Park, NJ: Macmillan Healthcare Information; 1987:153-163.
63. Harrison Y, Horne JA, Rothwell A. Prefrontal neuropsychological effects of sleep deprivation in young adults - a model for healthy aging? Sleep. 2000;23:1067-1073.
64. Croft RJ, Mackay AJ, Mills ATD, et al. The relative contributions of ecstasy and cannabis to cognitive impairment. Psychopharmacology. 2001;153:373-379.
65. Pihl RO, Paylan SS, Gentes-Hawn A, et al. Alcohol affects executive cognitive functioning differentially on the ascending versus descending limb of the blood alcohol concentration curve. Alcohol Clin Exp Res. 2003;27:773-779.
66. Dafters RI, Hoshi R, Talbot AC. Contribution of cannabis and MDMA ("ecstasy") to cognitive changes in long-term polydrug users. Psychopharmacology. 2004;173:405-410.
67. Lezak M. Neuropsychological Assessment. 3rd ed. New York: Oxford University Press; 1995:621-625.
68. Fitzgerald JL, Reid JJ. Interactions of methylenedioxymethamphetamine with monoamine transmitter release mechanisms in rat brain slices. Naunyn-Schmiedeberg's Arch Pharmacol. 1993;347:191-197.
69. Mateo Y, Ruiz-Ortega JA, Pineda J, et al. Inhibition of 5-hydroxytryptamine reuptake by the antidepressant citalopram in the locus coeruleus modulates the rat brain noradrenergic transmission in vivo. Neuropharmacology. 2000;39:2036-2043.
70. Hansen JP, Riddle EL, Sandoval V, et al. Methylenedioxymethamphetamine decreases plasmalemmal and vesicular dopamine transport: mechanisms and implications for neurotoxicity. J Pharmacol Exp Ther. 2002;300:1093-1100.
71. Baggot M, Heifets B, Jones RT, et al. Chemical analysis of ecstasy pills. JAMA. 2000;284:2190.
72. Parrot AC. Is ecstasy MDMA? A review of the proportion of ecstasy tablets containing MDMA, their dosage levels, and the changing perceptions of purity. Psychopharmacology. 2004;173:234-241.
73. Spruit IP. Monitoring synthetic drug markets, trends and public health. Subst Use Misuse. 2001;36:23-47.
74. Wolff K, Hay AWM, Sherlock K, et al. Contents of "ecstasy." Lancet. 1995;346:1100-1101